EPINEPHRINE and COVID 19

Overview

COVID 19 is the #10 most commonly reported adverse reaction for EPINEPHRINE, manufactured by Viatris Specialty LLC. There are 2,576 FDA adverse event reports linking EPINEPHRINE to COVID 19. This represents approximately 1.9% of all 135,553 adverse event reports for this drug.

Patients taking EPINEPHRINE who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COVID 19 is a less commonly reported adverse event for EPINEPHRINE, but still significant enough to appear in the safety profile.

Other Side Effects of EPINEPHRINE

In addition to covid 19, the following adverse reactions have been reported for EPINEPHRINE:

• DRUG INEFFECTIVE — 5,555 reports
• HEADACHE — 4,161 reports
• SINUSITIS — 3,917 reports
• FATIGUE — 3,762 reports
• DYSPNOEA — 3,216 reports
• PAIN — 3,156 reports
• NAUSEA — 3,135 reports
• PRODUCT DOSE OMISSION ISSUE — 2,999 reports
• OFF LABEL USE — 2,728 reports
• PNEUMONIA — 2,496 reports

Other Drugs Associated with COVID 19

The following drugs have also been linked to covid 19 in FDA adverse event reports:

Does EPINEPHRINE cause COVID 19?

COVID 19 has been reported as an adverse event in 2,576 FDA reports for EPINEPHRINE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COVID 19 with EPINEPHRINE?

COVID 19 accounts for approximately 1.9% of all adverse event reports for EPINEPHRINE, making it a notable side effect.

What should I do if I experience COVID 19 while taking EPINEPHRINE?

If you experience covid 19 while taking EPINEPHRINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages